101 patients with HER2+ MBC on pertuzumab and trastuzumab were included.
Most observed cardiotoxicity were mild, all occurred early within 24 months.
Presence of cardiovascular co-morbidities predicts treatment cardiotoxicity.
Risk-stratified de-escalation of long-term cardiac surveillance should be discussed.